These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28423503)

  • 1. Rap2b siRNA significantly enhances the anticancer therapeutic efficacy of adriamycin in a gold nanoshell-based drug/gene co-delivery system.
    Ding L; Sun R; Zhang X
    Oncotarget; 2017 Mar; 8(13):21200-21211. PubMed ID: 28423503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.
    Bai M; Shen M; Teng Y; Sun Y; Li F; Zhang X; Xu Y; Duan Y; Du L
    Oncotarget; 2015 Dec; 6(41):43779-90. PubMed ID: 26575421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery.
    Liu P; Yu H; Sun Y; Zhu M; Duan Y
    Biomaterials; 2012 Jun; 33(17):4403-12. PubMed ID: 22436800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
    Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
    J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
    Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
    J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flower-like gold nanoparticles for enhanced photothermal anticancer therapy by the delivery of pooled siRNA to inhibit heat shock stress response.
    Liu Y; Xu M; Zhao Y; Chen X; Zhu X; Wei C; Zhao S; Liu J; Qin X
    J Mater Chem B; 2019 Jan; 7(4):586-597. PubMed ID: 32254792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Promising Nanocarrier for Doxorubicin and siRNA Co-delivery by PDMAEMA-based Amphiphilic Nanomicelles.
    Cheng Q; Du L; Meng L; Han S; Wei T; Wang X; Wu Y; Song X; Zhou J; Zheng S; Huang Y; Liang XJ; Cao H; Dong A; Liang Z
    ACS Appl Mater Interfaces; 2016 Feb; 8(7):4347-56. PubMed ID: 26835788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylated carboxymethyl chitosan/calcium phosphate hybrid anionic nanoparticles mediated hTERT siRNA delivery for anticancer therapy.
    Xie Y; Qiao H; Su Z; Chen M; Ping Q; Sun M
    Biomaterials; 2014 Sep; 35(27):7978-91. PubMed ID: 24939077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
    Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
    Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rap2b, a novel p53 target, regulates p53-mediated pro-survival function.
    Zhang X; He Y; Lee KH; Dubois W; Li Z; Wu X; Kovalchuk A; Zhang W; Huang J
    Cell Cycle; 2013 Apr; 12(8):1279-91. PubMed ID: 23535297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer.
    Sadreddini S; Safaralizadeh R; Baradaran B; Aghebati-Maleki L; Hosseinpour-Feizi MA; Shanehbandi D; Jadidi-Niaragh F; Sadreddini S; Kafil HS; Younesi V; Yousefi M
    Immunol Lett; 2017 Jan; 181():79-86. PubMed ID: 27916629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
    Li X; Chen Y; Wang M; Ma Y; Xia W; Gu H
    Biomaterials; 2013 Jan; 34(4):1391-401. PubMed ID: 23164421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
    Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
    J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer.
    Dong D; Gao W; Liu Y; Qi XR
    Cancer Lett; 2015 Apr; 359(2):178-86. PubMed ID: 25592040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer.
    Lei Y; Tang L; Xie Y; Xianyu Y; Zhang L; Wang P; Hamada Y; Jiang K; Zheng W; Jiang X
    Nat Commun; 2017 Apr; 8():15130. PubMed ID: 28440296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
    Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
    Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
    Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene regulation with carbon-based siRNA conjugates for cancer therapy.
    Zhang L; Zheng W; Tang R; Wang N; Zhang W; Jiang X
    Biomaterials; 2016 Oct; 104():269-78. PubMed ID: 27472164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.
    Yonesaka K; Tamura K; Kurata T; Satoh T; Ikeda M; Fukuoka M; Nakagawa K
    Int J Cancer; 2006 Feb; 118(4):812-20. PubMed ID: 16108013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.